Stockholm-based startup Neko Health has successfully secured $260 million in a Series B funding round, elevating its valuation to $1.8 billion. The capital will facilitate Neko's expansion into new markets such as the U.S. and bolster its diagnostic capabilities, alongside plans to open additional clinics in response to a growing waitlist, which has surged to over 100,000. CEO Hjalmar Nilsonne highlighted the significant demand for innovative healthcare solutions, particularly as they prepare to establish a presence in the U.S.
Neko Health has raised $260 million in Series B funding, valuing the startup at $1.8 billion, signaling strong investor confidence in preventative healthcare solutions.
CEO Hjalmar Nilsonne emphasizes the rising demand for innovative healthcare approaches, noting a waitlist surge from 40,000 to over 100,000, highlighting their market potential.
The U.S. is a priority for Neko as it has the highest waitlist outside Europe, underpinning the company’s strategy to penetrate new markets driven by funding.
Investors such as Lightspeed Venture Partners and General Catalyst show strong belief in Neko's vision for transforming healthcare access and preventative measures in the market.
Collection
[
|
...
]